RA
ZSAN

Royce & Associates’s Zosano Pharma Corporation ZSAN Stock Holding History

Royce & Associates’s Portfolio ZSAN Stock Details ZSAN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-129
Closed -$910K – 1257
2015
Q1 		$910K Buy
+129
New +$968K ﹤0.01% 1030

Other funds holding ZSAN

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
LOAMU
Lombard Odier Asset Management (USA) New York $727M AUM 41.88% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $143M AUM 773.18% 1-Year Est. Return

Royce & Associates's ZSAN Position: Q2 2015 in Review

Royce & Associates sold out of Zosano Pharma Corporation (ZSAN) in Q2 2015, closing a stake of 129 shares — an estimated $910K sold.

Royce & Associates first reported a position in ZSAN in Q1 2015 and held it in 1 quarter. The position peaked at $910K in Q1 2015. 16 funds tracked by Wall St. Rank hold ZSAN as of Q2 2015.

  • Royce & Associates reported no remaining Zosano Pharma Corporation position as of Q2 2015 after selling out during the quarter.
  • Royce & Associates sold 129 Zosano Pharma Corporation shares in Q2 2015, an estimated $910K.
  • Royce & Associates first reported a position in Zosano Pharma Corporation in Q1 2015 and held it in 1 quarter.
  • Royce & Associates's Zosano Pharma Corporation position peaked at $910K in Q1 2015.
  • 16 funds tracked by Wall St. Rank held Zosano Pharma Corporation as of Q2 2015.

Based on Royce & Associates's 13F filing for Q2 2015, filed 10 Aug 2015.